Floatz logo

flt3 ligand

Diffuse Large B-cell Lymphoma (DLBCL)

Celldex TherapeuticsPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Diffuse Large B-cell Lymphoma (DLBCL) cohort.

Asset / SponsorPhaseRating
Plerixafor
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Fludarabine
AvenCell Therapeutics, Inc.
Phase 1/2CCC
tc011
TICAROS Co., Ltd.
Phase 1/2CC
crc01
Curocell Inc.
Phase 1/2CC
prt2527
Prelude Therapeutics
Phase 1CC

View all 12 →

Same molecule, other indications

flt3 ligand is also rated in:

Recurrent Renal Cell CancerDormant
B
Indicative ·
57 / 100
View asset →
Chronic Lymphocytic Leukemia (CLL)Dormant
CCC
Indicative ·
55 / 100
View asset →
Indolent B-cell LymphomasDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →